Nuedexta

RSS

Withdrawn

This medicine's authorisation has been withdrawn

dextromethorphan hydrobromide / quinidine sulfate
MedicineHumanWithdrawn

Greek is available via eTranslation, the European Commission's machine translation service.

Translate to Greek | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 February 2016 the European Commission withdrew the marketing authorisation for Nuedexta (dextromethorphan / quinidine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Jenson Pharmaceutical Services Ltd, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Nuedexta was granted marketing authorisation in the EU on 24 June 2013 for treatment of pseudobulbar affect (PBA) in adults. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Nuedexta is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (312.89 KB - PDF)

Προβολή

español (ES) (266.25 KB - PDF)

Προβολή

čeština (CS) (293.48 KB - PDF)

Προβολή

dansk (DA) (266.6 KB - PDF)

Προβολή

Deutsch (DE) (267.83 KB - PDF)

Προβολή

eesti (ET) (269.56 KB - PDF)

Προβολή

ελληνικά (EL) (320.31 KB - PDF)

Προβολή

français (FR) (267.84 KB - PDF)

Προβολή

hrvatski (HR) (283.73 KB - PDF)

Προβολή

italiano (IT) (264.25 KB - PDF)

Προβολή

latviešu (LV) (302.74 KB - PDF)

Προβολή

lietuvių (LT) (283 KB - PDF)

Προβολή

magyar (HU) (284.97 KB - PDF)

Προβολή

Malti (MT) (290.76 KB - PDF)

Προβολή

Nederlands (NL) (264.69 KB - PDF)

Προβολή

polski (PL) (284.4 KB - PDF)

Προβολή

português (PT) (286.28 KB - PDF)

Προβολή

română (RO) (268.86 KB - PDF)

Προβολή

slovenčina (SK) (285.42 KB - PDF)

Προβολή

slovenščina (SL) (286.75 KB - PDF)

Προβολή

suomi (FI) (262.95 KB - PDF)

Προβολή

svenska (SV) (265.02 KB - PDF)

Προβολή

Product information

български (BG) (1.24 MB - PDF)

Προβολή

español (ES) (638.47 KB - PDF)

Προβολή

čeština (CS) (994 KB - PDF)

Προβολή

dansk (DA) (630.24 KB - PDF)

Προβολή

Deutsch (DE) (690.2 KB - PDF)

Προβολή

eesti (ET) (627.09 KB - PDF)

Προβολή

ελληνικά (EL) (1.36 MB - PDF)

Προβολή

français (FR) (691.37 KB - PDF)

Προβολή

hrvatski (HR) (642.16 KB - PDF)

Προβολή

italiano (IT) (651.76 KB - PDF)

Προβολή

latviešu (LV) (994.32 KB - PDF)

Προβολή

lietuvių (LT) (810.7 KB - PDF)

Προβολή

magyar (HU) (994.57 KB - PDF)

Προβολή

Malti (MT) (1.04 MB - PDF)

Προβολή

Nederlands (NL) (663.87 KB - PDF)

Προβολή

polski (PL) (1.71 MB - PDF)

Προβολή

português (PT) (649.06 KB - PDF)

Προβολή

română (RO) (655.52 KB - PDF)

Προβολή

slovenčina (SK) (976.88 KB - PDF)

Προβολή

slovenščina (SL) (925.24 KB - PDF)

Προβολή

suomi (FI) (653.71 KB - PDF)

Προβολή

svenska (SV) (642.3 KB - PDF)

Προβολή

Íslenska (IS) (955.72 KB - PDF)

Προβολή

norsk (NO) (943.33 KB - PDF)

Προβολή
Latest procedure affecting product information:IAIN/0005
24/10/2014
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (167.05 KB - PDF)

Προβολή

español (ES) (153.71 KB - PDF)

Προβολή

čeština (CS) (160.1 KB - PDF)

Προβολή

dansk (DA) (154.47 KB - PDF)

Προβολή

Deutsch (DE) (154.57 KB - PDF)

Προβολή

eesti (ET) (153.66 KB - PDF)

Προβολή

ελληνικά (EL) (177.22 KB - PDF)

Προβολή

français (FR) (153.69 KB - PDF)

Προβολή

hrvatski (HR) (282.98 KB - PDF)

Προβολή

italiano (IT) (152.66 KB - PDF)

Προβολή

latviešu (LV) (164.45 KB - PDF)

Προβολή

lietuvių (LT) (154.89 KB - PDF)

Προβολή

magyar (HU) (160.64 KB - PDF)

Προβολή

Malti (MT) (160.78 KB - PDF)

Προβολή

Nederlands (NL) (153.75 KB - PDF)

Προβολή

polski (PL) (159.71 KB - PDF)

Προβολή

português (PT) (154.08 KB - PDF)

Προβολή

română (RO) (153.69 KB - PDF)

Προβολή

slovenčina (SK) (159.39 KB - PDF)

Προβολή

slovenščina (SL) (157.93 KB - PDF)

Προβολή

suomi (FI) (152.94 KB - PDF)

Προβολή

svenska (SV) (136.89 KB - PDF)

Προβολή

Íslenska (IS) (169.64 KB - PDF)

Προβολή

norsk (NO) (170.1 KB - PDF)

Προβολή

Product details

Name of medicine
Nuedexta
Active substance
  • dextromethorphan
  • quinidine
International non-proprietary name (INN) or common name
  • dextromethorphan hydrobromide
  • quinidine sulfate
Therapeutic area (MeSH)
Neurobehavioral Manifestations
Anatomical therapeutic chemical (ATC) code
N07XX59

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

Authorisation details

EMA product number
EMEA/H/C/002560
Marketing authorisation holder
Jenson Pharmaceutical Services Limited

Carradine House
237 Regents Park Road
London
N3 3LF
United Kingdom

Marketing authorisation issued
24/06/2013
Withdrawal of marketing authorisation
15/02/2016
Revision
2

Assessment history

This page was last updated on

Share this page